FCGR2A defines prognostic immune subtypes and drives tumor progression in hepatocellular carcinoma
FCGR2A acts as both a prognostic biomarker and an immune regulatory hub in HCC, anchoring a broader gene network that defines immune subtypes and predicts therapeutic responsiveness. Incorporating FCGR2A-based stratification may optimize immunotherapeutic strategies for HCC.
Authors
- Zhengwei Leng (ORCID: https://orcid.org/0000-0001-5740-7715)
- Shuoshuo Ma (ORCID: https://orcid.org/0009-0008-9450-6649)
- YaHui Chen (ORCID: https://orcid.org/0009-0009-0184-9536)
- Qinyan Yang (ORCID: https://orcid.org/0000-0002-1835-4355)
- Yuxin Liang (ORCID: https://orcid.org/0000-0001-6872-5030)
- Yuhao Su
- Xinpei Chen
- Deyuan Zhong
- Xing Chen (ORCID: https://orcid.org/0000-0002-9087-4232)
- Hongtao Yan
- Xiaolun Huang (ORCID: https://orcid.org/0000-0002-4993-0802)
- Fei Wang (ORCID: https://orcid.org/0000-0002-0079-6139)
- Ming Wang
Institutions
- Macau University of Science and Technology (MO)
- University of Macau (MO)
- Sichuan Cancer Hospital (CN)
- Chengdu Institute of Biology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1641420
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology of Sichuan Province